2
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
12
Breast Neoplasms
11
Lung Neoplasms
6
Prostatic Neoplasms
5
Colorectal Neoplasms
5
Uterine Cervical Neoplasms
4
Thyroid Neoplasms
2
Smoking Cessation
2
Motor Activity
2
Lymphoma
2
Hematologic Neoplasms
2
Communication
2
Uveal Melanoma
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tobacco Use Disorder
1
Tobacco Use Cessation
1
Thyroid Diseases
1
Substance-Related Disorders
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking
1
Sexual Dysfunction, Physiological
1
Sedentary Behavior
1
Rectal Neoplasms
1
Patient Preference
1
Patient Acceptance of Health Care
1
Papillomavirus Infections
1
Papillary Thyroid Microcarcinoma
1
Neoplasms, Plasma Cell
1
Interventions
pembrolizumab
91
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
25
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Focus Groups
×
Clear all
NCT07091565
2025-08-03
SPARC
King's College London
Enrolling by invitation
60 enrolled